IDEXX Laboratories, Inc.

IDXX Healthcare Diagnostics & Research

IDEXX Laboratories, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, up 10.4% from fiscal 2024. In the quarter to June 2026, revenue grew 9.66%, EPS grew 17.2%, free cash flow grew 111.4% and total debt fell 14.3%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; revenue growth for ten consecutive years, operating cash flow growth for three.

560.36 13.18 +2.41%
Market cap
$43.1B
P/E
39.1×
Fwd P/E
38.3×
Dividend yield
—
F-score
8/9
Altman Z
24.09
Beneish M
−2.50
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
74.21% 72.92% 66.20% 64.63%

+8 more TTM periods

Piotroski F-Score
9 8 8 8
ROA
33.65% 33.19% 31.89% 30.50%
ROIC
48.87% 48.68% 45.33% 43.47%
Return on Tangible Assets
119.33% 122.43% 104.65% 106.50%
Average Days of Receivables
50.27 49.55 46.85 49.65
Free Cash Flow per Share
15.67 13.28 11.89 10.78
Free Cash Flow
1,237.09 1,058.11 956.58 863.22
Other line items

Show all line items

Columns are period end dates